Abstract 11P
Background
Breast cancer is a heterogeneous disease with various histopathologic subtypes. As the prevalence of special types of breast cancer other than invasive carcinoma of no special type (NST) is low, limited data about the clinical behavior and prognosis according to the histologic types were documented with discordant results. The purpose of this study was to analyze the characteristics and the prognosis of rare histopathologic subtype of breast cancer compared with NST and to understand better for proper management.
Methods
A total of 133,969 patients were analyzed in this study among the patients who were registered in the Korean Breast Cancer Society Registry database between January 1996 and March 2019 in Korea.
Results
The prevalence of special types of breast cancer other than NST was 13.7% (n = 18,633). The patients with lobular, mucinous, tubular, papillary, and cribriform carcinoma presented as luminal A subtype much more than NST (77.6%, 74.6%, 77.2%, 57.4%, and 78.1% vs 47.5%, respectively, p < 0.001). A micropapillary carcinoma included more luminal B subtype with even high K-67 expression or positive HER2 than NST (40.9% vs 29.5%, p < 0.001). Typically, medullary and metaplastic carcinoma included more triple negative breast cancer (44.8% and 64.8% vs 13.5%, p < 0.001) than NST. In survival analysis, lobular (HR 0.879, p = 0.029), mucinous (HR 0.529, p < 0.001), tubular (HR 0.781, p < 0.001), papillary (HR 0.728, p < 0.001), medullary (HR 0.500, p < 0.001), and cribriform carcinoma (HR 0.291, p = 0.001) showed better overall survival than NST, and metaplastic carcinoma (HR 1.995, p < 0.001) showed worse outcome significantly. However, after adjusting for age, stage, molecular subtypes, grade, and lymphovascular invasion, only metaplastic carcinoma showed different overall (HR 1.762, p < 0.001) and breast cancer-specific survival (HR 1.685, p = 0.012) from NST.
Conclusions
In conclusion, invasive breast cancer had specific clinical and pathologic features according to the histopathologic subtype. However, special types of breast cancer other than NST have similar survival outcomes compared to NST when adjusting for other prognostic factors, except for metaplastic carcinoma.
Clinical trial identification
Editorial acknowledgement
This research was supported by the Korean Breast Cancer Society.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract